Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

BACKGROUND: GSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma. The objective of this study was to evaluate GSK2190915 efficacy, dose–response and safety in subjects with persistent asthma treated with short-acting beta2-agonists (SA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Follows, Richard MA, Snowise, Neil G, Ho, Shu-Yen, Ambery, Claire L, Smart, Kevin, McQuade, Barbara A
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732081/
https://ncbi.nlm.nih.gov/pubmed/23682661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1465-9921-14-54
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados